Clinical Trials
10 trialsNCT04310020 2026-05-13
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04929041 2026-05-13
Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative
National Cancer Institute (NCI)
Phase 2/3 Suspended
NCT02888743 2026-04-13
Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04989283 2023-09-26
Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00040794 2013-06-05
Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005065 2013-06-04
Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00020709 2013-02-27
Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT00042835 2013-02-01
Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00005838 2013-01-23
Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT00387374 2013-01-17
Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab
National Cancer Institute (NCI)
Phase 2 Completed